Loading patent…
AssigneesRegents of the University of Minnesota, The University of North Carolina at Chapel Hill, Albert-Ludwigs-Universität Freiburg, St. Jude Children's Research Hospital
InventorsBruce R. Blazar, Brent Koehn, Peter J. Murray, Jenny P. Y. Ting, Robert Zeiser, Jeff S. Miller
Estimating the term…
In one aspect, a method of treating a subject having or at risk of having graft-versus-host disease (GvHD) generally includes administering to the subject a plurality of myeloid-derived suppressor cells (MDSCs) effective to ameliorate at least one symptom or clinical sign of graft-versus-host disease compared to a suitable control subject. In another aspect, a method of treating a tumor in a subject generally includes administering to the subject an anti-tumor therapy and co-administering to the subject an inflammasome inciting agent in an amount effective to increase inflammasome activation of MDSCs sufficiently to reduce suppressor function of the MDSCs.
A method of treating a subject having or at risk of having graft-versus-host disease (GvHD), wherein said method comprises administering to the subject a plurality of myeloid-derived suppressor cells (MDSCs), wherein said MDSCs lack expression of apoptosis-associated speck-like protein containing a CARD (ASC) polypeptides, and wherein said MDSCs comprise a genetic deletion of nucleic acid encoding said ASC polypeptides.
A method of treating a subject having or at risk of having graft-versus-host disease (GvHD), wherein said method comprises administering to the subject a plurality of myeloid-derived suppressor cells (MDSCs), and
Dependencies are inferred from the claim text.